Pfizer tops profit estimates on strong Eliquis demand

• Pfizer raised its full-year revenue guidance floor to $60.5 billion from $59.5 billion, while maintaining the upper end at $62.5 billion
• Strong demand for blood thinner Eliquis was the primary driver behind the profit beat
• The company is relying on newer medicines and its $10 billion Metsera acquisition to offset declining COVID revenue and establish presence in the obesity treatment market

Pfizer Tops Profit Estimates on Strong Eliquis Demand

Key Financial Results:

Pfizer exceeded Wall Street's second-quarter profit expectations, reporting adjusted earnings of 77 cents per share. The company raised its full-year revenue guidance to $60.5-$62.5 billion, up from the previous range of $59.5-$62.5 billion, representing a $1 billion increase at the lower end.

Main Drivers:

Strong demand for Eliquis, Pfizer's blood-thinning medication, was the primary driver behind the beat. The performance signals robust prescription trends for one of the company's key revenue generators.

Strategic Focus:

Pfizer is actively working to offset declining COVID-19 product revenue by relying on newer medicines and reducing dependence on aging blockbuster drugs. The company recently completed a significant $10 billion acquisition of Metsera, aimed at establishing a competitive position in the rapidly expanding obesity treatment market—a sector attracting substantial investor interest.

Market Implications:

The results demonstrate Pfizer's ability to maintain profitability amid the post-pandemic transition period. Investors are closely monitoring whether the Metsera acquisition can deliver meaningful returns and help Pfizer capture market share in obesity treatments, one of the pharmaceutical industry's fastest-growing segments.

Date: The earnings were released on August 4, 2026.

The positive results suggest Pfizer's diversification strategy is gaining traction, though success in the obesity market remains critical for long-term growth prospects. The raised guidance reflects management's increased confidence in achieving full-year targets despite headwinds from COVID product decline.